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Abstract
Established tumors build a stressful and hostile microenvironment that blocks the development of protective innate
and adaptive immune responses. Different subsets of immunoregulatory myeloid populations, including dendritic
cells, myeloid-derived suppressor cells (MDSCs) and macrophages, accumulate in the stressed tumor milieu and
represent a major impediment to the success of various forms of cancer immunotherapy. Specific conditions and
factors within tumor masses, including hypoxia, nutrient starvation, low pH, and increased levels of free radicals,
provoke a state of “endoplasmic reticulum (ER) stress” in both malignant cells and infiltrating myeloid cells. In order
to cope with ER stress, cancer cells and tumor-associated myeloid cells activate an integrated signaling pathway
known as the Unfolded Protein Response (UPR), which promotes cell survival and adaptation under adverse
environmental conditions. However, the UPR can also induce cell death under unresolved levels of ER stress. Three
branches of the UPR have been described, including the activation of the inositol-requiring enzyme 1 (IRE1), the
pancreatic ER kinase (PKR)-like ER kinase (PERK), and the activating transcription factor 6 (ATF6). In this minireview,
we briefly discuss the role of ER stress and specific UPR mediators in tumor development, growth and metastasis.
In addition, we describe how sustained ER stress responses operate as key mediators of chronic inflammation and
immune suppression within tumors. Finally, we discuss multiple pharmacological approaches that overcome the
immunosuppressive effect of the UPR in tumors, and that could potentially enhance the efficacy of cancer
immunotherapies by reprogramming the function of tumor-infiltrating myeloid cells.
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Background
The Endoplasmic Reticulum (ER) plays a fundamental
role in the homeostatic synthesis, folding and glycosyla-
tion of nascent transmembrane and secretory proteins
[1]. In addition, the ER acts as the primary organelle for
calcium storage and biosynthesis of lipids and sterols in
eukaryotic cells [2]. The physiological activity of the ER
is tightly controlled by intrinsic processes such as cell
differentiation, proliferation status and activation signals,
as well as by exogenous factors in the microenvironment
[3]. For instance, hostile conditions in the tumor milieu
such as hypoxia, nutrient starvation, low pH, and free rad-
icals can rapidly disrupt the protein folding capacity of the
ER, thereby triggering a state of cellular “ER stress” [4].
The accumulation of misfolded proteins in the ER acti-
vates the Unfolded Protein Response (UPR), which is an
integrated signaling pathway that attempts to restore the
homeostasis of this organelle. The UPR drives multiple
adaptive and survival processes, including the attenuation
of de novo protein synthesis, the regulation of the ER
membrane, the degradation of misfolded proteins, and the
selective induction of mediators and chaperones that pro-
mote the correct folding of proteins [5]. However, when
ER stress is severe and prolonged, the same UPR media-
tors that regulate survival can trigger the induction of cel-
lular death [6]. Overactivation of UPR mediators has been
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implicated in several pathological processes, including can-
cer, diabetes, and cardiovascular and neurodegenerative
diseases [4]. In addition, recent studies have demonstrated
the importance of the UPR in the overall modulation of
chronic inflammation in cancer [7–10]. In this review, we
discuss how ER stress and aberrant activation of the UPR
alter the function of malignant cells and cancer-associated
myeloid cells, and how this process controls anti-tumor
immunity. We also discuss various pharmacological ap-
proaches to overcome the immunosuppressive effect of ER
stress in tumors and the potential of these strategies as
new cancer immunotherapies.
Review
ER stress sensors and the UPR
The UPR plays a crucial role in mediating cellular adap-
tation to ER stress. Three major ER-localized trans-
membrane proteins trigger this adaptive pathway: the
inositol-requiring enzyme 1 (IRE1), the pancreatic ER
kinase (PKR)-like ER kinase (PERK), and the activating
transcription factor 6 (ATF6) [4]. In the absence of ER
stress, these three sensors are bound and maintained in
an inactive form by the HSP70-type chaperone BiP/
GRP78 [11–13]. Because BiP exhibits a higher affinity
for misfolded proteins, the induction of ER stress
causes the dissociation of BiP from the sensors, leading
to their activation and subsequent initiation of the
UPR. The mechanisms by which the major mediators
of the UPR regulate cellular responses under ER stress
are as follow:
IRE1
The Type I ER transmembrane protein IRE1 is a dual
enzyme with serine/threonine-protein kinase and endori-
bonuclease activity that exists in two conserved isoforms:
IRE1α and IRE1β [14, 15]. IRE1α is ubiquitously
expressed, whereas IRE1β expression is limited to the gut
[14, 16]. At steady state, the chaperone BiP maintains
IRE1α in its monomeric form, thereby impeding its activa-
tion. During ER stress, the accumulation of misfolded pro-
teins titrate BiP away from IRE1α, allowing IRE1α
dimerization, autophosphorylation, and a conformational
shift that licenses its C-terminal endoribonuclease domain
to excise 26 nucleotides from the X-box binding protein 1
(Xbp1) mRNA in the cytosol [17–19]. The spliced tran-
script is subsequently re-ligated by the tRNA ligase RtcB
[20], resulting in a critical reading frame shift that allows
the generation of the functionally mature XBP1. This tran-
scription factor effectively alleviates ER stress by inducing
the expression of chaperones, redox-dependent foldases,
and glycosyltransferases. Beyond its canonical functions in
the UPR, XBP1 can also modulate ER stress-independent,
context-specific processes such as response to hypoxia
[21], lipid metabolism [22], estrogen receptor activity [23]
and the transcriptional induction of pro-inflammatory
cytokines [24], among many others.
Although most of the IRE1α signaling events are associ-
ated with the induction of pro-survival pathways, IRE1α
can also trigger apoptosis under severe or lethal ER stress.
As such, IRE1α can degrade non-Xbp1 mRNA targets
through regulated IRE1α-dependent decay (RIDD), a
phenomenon that has been previously associated with the
induction of apoptosis [25]. Moreover, active IRE1α com-
plexes with the adaptor protein TNF-receptor-associated
factor 2 (TRAF2), which recruits the apoptosis-signal-
regulating kinase (ASK1), leading to cell death or autoph-
agy [26–28]. Additionally, IRE1α-linked apoptosis has
been reported to be mediated through the activation of
the c-Jun N-terminal kinase (JNK) and a subsequent in-
hibition of BCL2 family members [29]. Furthermore, acti-
vation of XBP1 through IRE1α induces the expression of
the HSP40 family member P58IPK, which binds and in-
hibits PERK, overcoming the PERK-mediated translational
block [30]. Although this event can represent the termin-
ation of the UPR under transient ER stress, it may also
trigger apoptosis under severe conditions of stress through
the translation of pro-apoptotic mediators [31, 32]. Thus,
IRE1α can play a dual role in the cellular responses against
ER stress by promoting both survival and cell death.
PERK
Under homeostatic conditions, the type I ER trans-
membrane protein PERK (or eIF2aK3) is maintained in
an inactive form also through complexing with BiP
[33]. After the induction of ER stress and release of BiP,
PERK activates through oligomerization and autophos-
phorylation, leading to the phosphorylation of various
PERK substrates, including the eukaryotic translation
initiation factor 2 alpha (eIF2α), the NF-E2-related fac-
tor 2 (Nrf2), the forkhead box O proteins (FOXO), and
the second messenger diacyglycerol (DAG) [34]. The
increased susceptibility of PERK null primary cells and
tumor cells to ER stress-induced cell death suggests the
major role of PERK in pro-survival mechanisms [35, 36].
The best-characterized PERK-linked effect is the phos-
phorylation of eIF2α, which serves as a common regulator
of the integrated stress responses in cells. In addition to
PERK, three different kinases, the double-stranded RNA-
dependent protein kinase (PKR), the hemin-regulated in-
hibitor (HRI), and the nutrient starvation activated kinase
GCN2, phosphorylate eIF2α in response to specific forms
of stress [37]. Phospho-eIF2α inhibits nucleotide exchange
on the eIF2 complex, attenuating translation of most
mRNAs, thereby alleviating additional sources of ER stress
[37]. In addition, it increases the Cap-independent expres-
sion of a limited number of proteins that eventually
control the cell fate during stress, including the activating
transcription factor 4 (ATF4). Thus, phosphorylation of
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eIF2α by PERK serves as a major mechanism to de-
crease protein synthesis and thereby counter the accu-
mulation of misfolded proteins in the stressed ER. In
addition, active PERK phosphorylates Nrf2, which then
translocates to the nucleus and induces the expression
of multiple cellular redox transcripts that alleviate the
effects of stress-induced reactive oxygen species (ROS)
[38]. Also, activation of FOXO proteins by PERK nega-
tively regulates AKT activity and therefore converts
stressed cells from anabolic metabolic programs into
those leading to nutrient catabolism [39]. Thus, the ac-
tivation of PERK plays a fundamental role in the meta-
bolic adaptation of cells to ER stress.
Phosphorylation of eIF2α induces the activation of
ATF4 that directly regulates the survival of the stressed
cells through the induction of autophagy. Interestingly,
ATF4 induction after uncontrolled or chronic ER stress
regulates the expression of the pro-apoptotic protein
CAAT/enhancer binding protein (C/EBP) homologous
protein (CHOP/Ddit3), which plays a key role in the in-
duction of cell death by stress [40]. The mechanism by
which PERK activity plays a dual role in the survival of
stressed cells has been recently demonstrated. The induc-
tion of ATF4 after PERK activation results in the transient
expression of the microRNA miR-211, which temporarily
blocks the transcription of pro-apoptotic CHOP. However,
after the expiration of miR-211, CHOP transcription pro-
ceeds and the cells undergo apoptosis [41]. Therefore,
similar to the role played by IRE1α, the activation of PERK
can mediate pro-survival or pro-apoptotic effects.
ATF6
ATF6 is an ER-resident type II transmembrane protein
that exists as 2 homologs (ATF6α and ATF6β) and serves
as a precursor for a cytoplasmic N-terminal bZIP tran-
scription factor [42]. Upon dissociation from BiP, ATF6α
translocates to the Golgi apparatus via coat protein
COPII–covered vesicles where it results cleaved by site 1
and site 2 proteases, enabling its transcription factor po-
tential [13]. ATF6α target genes regulate the folding and
glycosylation of de novo proteins, thereby regulating the
survival of stressed cells [43]. In addition, several common
targets of ATF6α are also regulated by XBP1, suggesting
potential overlapping effects of IRE1α and ATF6α. Al-
though the role of ATF6α and ATF6β upon ER stress re-
mains less critical than that induced by IRE1α and PERK,
the knockdown of Atf6 results in lower survival rates after
specific chemically-induced ER stress, indicating that
ATF6α is indeed protective in the responses induced by
pharmacological ER stress [43].
Role of the UPR in malignant cells
The key interaction between the UPR and tumorigenesis
has been comprehensively discussed in previous reviews
[1, 4, 5, 34]. Malignant cells thrive under ER stress-
inducing conditions such as hypoxia, nutrient deprivation,
and low pH. In addition, cancer cells generate reactive
metabolic byproducts that avidly modify ER-resident pro-
teins and chaperones. Notably, the induction of various
UPR-related factors has been commonly reported in pa-
tients with various cancer types and their overexpression
usually correlates with poor prognosis and resistance to
therapy [21, 44–46]. Interestingly, treatment of tumor-
bearing mice with the ER stress inducer thapsigargin in-
creased tumor growth, whereas global UPR inhibition
using chemical chaperones, such as 4-Phenylbutyric acid
(4-PBA) or tauroursodeoxycholic acid (TUDCA), delayed
tumor progression and metastasis [9, 47].
Seminal studies have determined the cancer cell-
intrinsic protumoral role of the IRE1α- XBP1 and the
PERK-eIF2α pathways in vivo. Implantation of malig-
nant cells or transformed fibroblasts lacking IRE1α/
XBP1 or PERK/eIF2α in mice resulted in reduced
tumor growth, which was attributed to low angiogen-
esis and increased sensitivity of the cancer cells to ER
stress inducers, including hypoxia and high levels of
ROS [35]. Accordingly, targeting IRE1α or PERK signal-
ing in vivo with specific small-molecule inhibitors has
shown significant therapeutic effects in various preclin-
ical models of disease [48–52]. More recently, XBP1
was demonstrated to foster triple negative breast cancer
progression by cooperating with HIF1α to support
tumor-initiating cell function and metastatic capacity
under hypoxia [21]. XBP1 contributes to the pathogen-
esis of multiple myeloma [53], and has been implicated
in cancer cell de-differentiation, susceptibility to oncov-
irus infection and the epithelial-to-mesenchymal transi-
tion [54]. Andrew Hu and colleagues have elegantly
demonstrated constitutive IRE1α-XBP1 activation in
chronic lymphocytic leukemia cells, which promoted
their pathogenesis in vivo [48]. In addition, inhibiting
IRE1α function by overexpressing a dominant negative
IRE1α variant significantly increased overall host survival
by decreasing tumor growth rate and angiogenesis in a
model of glioma [55]. Recent studies have also indicated
that IRE1α-XBP1 signaling supports the aggressiveness of
pancreatic cancer cells in xenograft models [56].
Similar to the effect induced by IRE1α-XBP1 signaling,
the activation of PERK-eIF2α has also been implicated in
the development of several malignancies, including breast,
lung, and liver carcinoma [36, 47]. In those models, dele-
tion of Perk rendered malignant cells highly susceptible to
the cell death induced after exposure to hypoxia, DNA
damage, low levels of nutrients, and high levels of reactive
oxygen species [57]. Furthermore, the absence of PERK-
eIF2α signaling impaired the ability of breast cancer cells
to migrate and invade, thereby decreasing their ability to
metastasize in vivo [49, 58, 59]. Therefore, the inhibition
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of PERK resulted in cancer cell apoptosis and signifi-
cant anti-tumor effects [43]. As such, silencing of Perk
increased the therapeutic efficacy of treatments based
on the depletion of amino acids in T cell leukemia [60],
and sensitized chronic myeloid leukemia (CML) cells to
the apoptosis induced by the BCR/ABL inhibitor, ima-
tinib mesylate [61]. Thus, the intrinsic effects of a con-
trolled UPR in cancer cells appear to favor tumor
growth and metastasis through the promotion of malig-
nant cell survival, angiogenesis and chemoresistance,
thus justifying the use of specific UPR inhibitors for the
treatment cancer.
Although activation of the UPR has been primarily as-
sociated with cancer cell survival and tumor progression,
some studies suggest that molecular factors in this path-
way could also suppress tumor development in certain
contexts. For instance, increased oncogenic transform-
ation has been evidenced in fibroblasts after inhibiting
the PERK target eIF2α [62], and increased proliferation
and mammary tumor formation has been reported upon
expression of a dominant-negative form of PERK in
mammary epithelial cells [63]. Furthermore, in the con-
text of acute myeloid leukemia, increased expression of
ER stress response markers correlates with better prog-
nosis in patients with this disease [64]. Taken together,
these studies indicate that the effects of the UPR in can-
cer cells is context-dependent and that variables such as
the stage of cancer progression and the cellular source
of malignancy are critical determinants of whether this
pathway plays either a pro-tumorigenic or anti-tumoral
role.
ER-stressed cancer cells efficiently manipulate myeloid
functions
Although the effect of the UPR in the survival/death of
malignant cells has been extensively studied during the
last decade, its role in the modulation of anti-tumor
immunity has remained minimally characterized. Superior
tolerogenic activity is observed in tumor-infiltrating mye-
loid cells compared with those located outside the tumors,
suggesting a role for the tumor-stressed microenviron-
ment in the control of myeloid cell function [65, 66].
Initial in vitro studies reported paracrine effects of tumor
cells undergoing ER stress on dendritic cells (DCs), mac-
rophages, and myeloid-derived suppressor cells (MDSCs).
Pharmacological induction of UPR in cancer cells trig-
gered “transmissible” ER stress in myeloid cells, as evi-
denced by the upregulation of UPR-related elements in
these innate immune cells upon exposure to supernatants
from treated cancer cells [67]. In this system, induction of
ER stress markers in myeloid cells correlated with their
decreased ability to induce T cell responses, elevated ex-
pression of suppressive factors such as arginase I and
prostaglandin E2 (PGE2), and upregulation of various
cytokines including IL-6, IL-8, TNFα, and IL-23 [67] [10].
The impairment of myeloid cells exposed to supernatants
from ER-stressed cancer cells to activate T cell responses
was associated with a reduction in their antigen-presenting
capacity [68]. Moreover, DCs conditioned in vitro with su-
pernatants from ER-stressed cancer cells were transformed
into MDSCs and facilitated tumor growth after adoptive
transfer into tumor-bearing mice [10] (Fig. 1). While these
studies suggested that ER-stressed cancer cells release
soluble factors that more efficiently modulate immune cell
function, it remained mechanistically and functionally
elusive whether myeloid-intrinsic UPR factors were indeed
responsible for the correlative changes described. Interest-
ingly, administration of the ER stressor thapsigargin to
tumor-bearing mice accelerated cancer progression and
enhanced the accumulation and immunosuppressive cap-
acity of MDSC, a process that could be attenuated upon
in vivo treatment with the ER stress chemical chaperone,
4-PBA [9]. PERK has been implicated in blocking the ef-
fects of type 1 interferon potentially through direct regula-
tion of the interferon receptor [69]. Previous results also
showed that activation of PERK and the subsequent phos-
phorylation of eIF2α increased the activity of NF-kB by
controlling the translation, but not the degradation, of the
NF-kB inhibitor IkB [70]. Similarly, activation of IRE1α
and ATF6 induced the phosphorylation of IkB and the sub-
sequent activation of NF-kB in a manner dependent upon
TRAF2 and Akt90, respectively [70, 71]. However, the po-
tential interaction between the UPR and NF-kB in myeloid
cells within tumors remains to be explored. These studies
indicate that cancer cells undergoing ER stress can avidly
modulate the phenotype of tumor-infiltrating myeloid
cells.
Cancer cell-intrinsic ER stress and immunogenic cell death
(ICD)
Chemotherapeutic agents of the anthracycline family have
been shown to trigger the UPR in cancer cells and this
process was associated with the induction of immuno-
genic cell death (ICD), activation of myeloid cell function,
and protective anti-tumor immunity [72]. Nonetheless, it
remains unclear how the induction ER stress in malignant
cells could result in the development of suppressive or im-
munogenic responses. ICD induction by ER stress ap-
pears to be mediated through a significant elevation of
ROS levels and a subsequent activation of the NLRP3-
inflammasome [4, 73]. However, the accumulation of
ROS also remains as a major mechanism of T cell sup-
pression by myeloid cells in tumors [74]. The fine bal-
ance between the levels of ROS and the specific ROS
mediators could explain the opposite effects induced by
stressed cancer cells on anti-tumor immunity (Fig. 2).
Alternatively, the different consequences of tumor cells
undergoing ER stress could also be explained by the
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simultaneous development of suppressive and immuno-
genic UPR in different subsets within the malignant cell
population. Another plausible explanation is that moder-
ate but sustained ER stress triggers immunosuppressive
effects, whereas a robust/lethal UPR could result in ICD
(Fig. 2). Interestingly, superior anti-tumor immune re-
sponses were observed in mice injected with BiP-deficient
fibrosarcoma cells, presumably due to lethal overactivation
of ER stress sensors that promotes ICD [75]. Hence, sus-
tained ER stress responses occurring in transformed cells
could promote immunosuppression, while the dramatic
overactivation of the UPR upon acute chemo- or radio-
therapy regimens may promote immunostimulatory re-
sponses (Fig. 2). Strikingly, however, XBP1 was recently
shown to prevent ICD in metastatic colorectal cancer cells
upon combination treatment with epidermal growth fac-
tor receptor blockers and chemotherapy [76].
Intrinsic roles of the UPR in tumor-associated myeloid
cells
Elevated expression of UPR mediators in tumors corre-
lated with stage, aggressiveness, and low survival in pa-
tients with different malignancies. However, the link
between the induction of ER stress in the tumor stroma
and immunosuppression in individuals with cancer has
not been appreciated over the last 10 years. Initial stud-
ies showed the role of UPR in the regulation of inflam-
mation through modulation of the production of ROS
and the activation of NF-kB, Jnk and IRF3 [1]. Most re-
cently, however, various groups have demonstrated that
sustained ER stress responses also act as crucial drivers
of myeloid cell dysfunction in tumors [7, 8, 77].
IRE1α − XBP1 signaling is required for the optimal
homeostatic differentiation of plasma cells, eosinophils
and some DC populations [78–80]. Optimal TLR-
driven pro-inflammatory cytokine production in macro-
phages has been demonstrated to be mediated by XBP1
[24]. In a model of acute lung injury, neutrophils infil-
trating early lesions exhibited signs of ER stress, and
XBP1 expression by this specific myeloid population
was required for disease progression [81]. Interestingly,
the potential role of this arm of the UPR in controlling
the regulatory phenotype of tumor-associated myeloid
cells has recently emerged as a key mediator of immune
suppression in cancer (Fig. 3). In ovarian cancer, dys-
functional tumor-associated DCs (tDCs) showed robust
Fig. 1 Hostile conditions in the tumor microenvironment such as hypoxia, nutrient deprivation and ROS can provoke ER stress and trigger the
UPR in various tumor-resident cell types. Intrinsic ER stress responses in cancer cells ensure their survival under hypoxic conditions, increase
expression of pro-angiogenic factors, promote metastasis and inhibit the presentation of their own antigens. Myeloid-intrinsic ER stress responses
mediate reprogramming towards immunosuppressive and tolerogenic phenotypes. Induction of ER stress in myeloid cells may occur via transmissible
factors released by ER-stressed cancer cells in the same milieu. Intracellular generation and accumulation of lipid peroxidation byproducts can further
elicit intrinsic ER stress responses in myeloid cells. ER stress sensors therefore emerge as attractive targets for developing new immunotherapeutic
approaches that may synergize with standard cancer treatments
Fig. 2 The severity of ER stress and the levels of ROS in cancer cells
can determine the outcome of immune responses within the tumor
milieu. Intense ER stress responses induced by chemo- or
radiotherapy increase ROS in cancer cells to levels that can promote
immunogenic cell death (ICD), thus enhancing anti-tumor immunity.
Moderate but sustained ER stress responses in cancer cells support
tolerogenic and immunosuppressive functions in tumor-infiltrating
myeloid cells, a process that cripples anti-cancer immunity
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expression of ER stress markers and sustained activa-
tion of the IRE1α − XBP1 arm of the UPR, compared
with DCs residing in non-tumor locations [7]. Persist-
ent ER stress responses in tDCs were provoked by
intracellular ROS that promoted lipid peroxidation and
subsequent generation of reactive aldehyde byproducts
such as 4-hydroxynonenal (4-HNE), which modified
several ER-resident chaperones and proteins [7]. Treat-
ment of tDCs with ROS-scavenging vitamin E or hydra-
zine derivatives that avidly sequester 4-HNE ameliorated
ER stress responses in tDC [7]. Conditional deletion of
Xbp1 in DCs resulted in delayed ovarian cancer progres-
sion and this process was mediated through the induction
of protective T cell anti-tumor immunity. Additional ex-
periments further confirmed that tDCs lacking XBP1 were
immunostimulatory rather than tolerogenic. Mechanistic-
ally, abnormal activation of XBP1 metabolically repro-
grammed DCs towards aberrant triglyceride biosynthesis
and uncontrolled lipid accumulation, a process that was
associated with reduced tDC antigen-presenting capacity.
Interestingly, aberrant lipid accumulation and the produc-
tion of oxidized fatty acids are common tolerogenic char-
acteristics of tumor-infiltrating DCs and MDSCs [82–84].
Consistent with the immunogenic effects induced upon
deleting or silencing Xbp1 in tDCs, targeting lipid uptake
or inhibiting key mediators of fatty acid oxidation has
been shown to boost anti-cancer immunity by enhancing
myeloid cell function in the tumor microenvironment
[82–84]. While there is a clear interaction between the in-
duction of ER stress and the metabolic reprogramming of
myeloid cells in tumors, it remains unknown whether the
tolerogenic effects induced by the accumulation of lipids
in myeloid cells are solely mediated through IRE1α-XBP1
signaling or whether additional mediators participate in
this process. Nevertheless, recent studies by Gabrilovich
and colleagues have elegantly reinforced the crucial im-
munoregulatory role of aberrant IRE1α-XBP1 signaling in
human cancer-associated myeloid cells [85]. In diverse hu-
man cancer specimens, upregulation of ER stress-related
gene signatures and surface expression of the lectin-type
oxidized LDL receptor-1 (LOX-1) distinguished high-
density neutrophils from low-density immunosuppressive
polymorphonuclear MDSCs (PMN-MDSCs). Strikingly,
pharmacological induction of ER stress in human neutro-
phils rapidly triggered LOX-1 upregulation and trans-
formed them into immunosuppressive cells in an IRE1α/
XBP1-dependent manner. These recent studies indicate
that the sustained activation of the IRE1α-XBP1 arm of
the UPR promotes immunosuppression in cancer hosts by
modulating the activity of tumor-associated DC, neutro-
phils, and MDSCs. Furthermore, a recent study showed
that IRE1α-XBP1 signaling also shapes the pro-tumoral at-
tributes of macrophages in cancer [86]. Through syner-
gism between the IL-4 and IL-6 signaling pathways to
activate IRE1α, tumor-associated macrophages acquire a
secretory phenotype that enables the infiltration of meta-
static cancer cells via Cathepsin proteases.
In addition to the role of IRE1α-XBP1 in the suppressive
function of tumor-infiltrating myeloid cells, recent studies
have demonstrated a major function for the UPR down-
stream target CHOP as a key regulator of MDSC activity
and turnover in tumors [77]. While the pro-apoptotic
Fig. 3 IRE1ɑ-XBP1 is one of the arms of UPR that polarizes tumor-infiltrating myeloid cells into highly immunosuppressive populations. Over activation
of IRE1ɑ-XBP1 pathway by the byproduct adduct 4-hydroxy-trans-2-nonenal (4-HNE) in the tumor microenvironment (TME) shifts tumor-infiltrating
dendritic cells towards a tolerogenic phenotype that promotes cancer cell growth. IRE1ɑ-XBP1 activation upregulates lectin-type oxidized LDL
receptor-1 (LOX-1) that converts high density anti-tumor neutrophils to low density immunosuppressive polymorphonuclear myeloid cells (PMN-
MDSCs). IL-4 and IL-6 signals synergize with IRE1ɑ-XBP1 to enhance the ability of tumor-associated macrophages to secret Cathepsin proteases, which
facilitate cancer cell invasion and metastasis
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effect CHOP has been appreciated for years, it is now evi-
dent that it can also regulate other cellular functions inde-
pendent of the induction of apoptosis. In fact, CHOP
expression controlled the polarization of macrophages
into “alternatively activated” cells and directly regulated
the expression of various cytokines, including IL-23, IL-
1β, and IL-6 [87–89]. Interestingly, CHOP levels can be
increased not only upon activation of the UPR, but also
through other immunoregulatory mechanisms, including
nutrient starvation, TLR agonists, and increased ROS
accumulation, suggesting its common involvement in
multiple stress pathways. Elevated CHOP expression was
found in MDSCs infiltrating mouse and human tumors,
which directly correlated with the ability of MDSC to im-
pair T cell responses [8, 77]. Interestingly, the injection of
CHOP-competent cancer cells into systemic Chop-defi-
cient mice or Chop-null bone marrow chimeras resulted
in a significant anti-tumor effect mediated by CD8+ T
cells, suggesting the importance of hematopoietic-intrinsic
CHOP in tumor growth and tumor-induced tolerance
[77]. Furthermore, MDSCs isolated from tumor-bearing
mice devoid of CHOP exhibited reduced ability to block T
cell responses and impaired expression of major inhibitory
pathways, while demonstrating an extraordinary ability to
prime T cell proliferation and induce anti-tumor effects.
Additional studies showed the potential role of CHOP in
the regulation of C/EBPβ, a pathway known to globally
regulate MDSC function. This resulted in an increased
production of IL-6 that played a primary role in the effects
induced by CHOP. Thus, the inhibition of CHOP could
represent a major strategy to overcome the tolerogenic
function of MDSCs and other myeloid suppressive cells in
tumors. Similar to the effect of the endogenously pro-
duced ROS in the activation of IRE1α-XBP1 in tDCs [7],
we found that pharmacological scavenging of ROS
prevented the induction of CHOP in tumor-associated
myeloid cells [77], suggesting the common role of ROS in
the induction of UPR in cancer-infiltrating myeloid cells.
Although the induction of CHOP after ER stress is pri-
marily mediated through ATF4, it remains unknown the
role of the CHOP-independent ATF4 effects in tumor-
associated myeloid cells. Nevertheless, a seminal study by
Condamine and colleagues showed the role of ER stress in
the regulation of MDSC survival in tumors [8]. Induc-
tion of ER stress was detected preferentially in tumor-
infiltrating MDSCs and promoted MDSC apoptosis
through TNF-related apoptosis induced ligand receptor
2 (DR5) and caspase 8 activation [14]. Thus, DR5 ago-
nists could be considered as potential strategies for
controlling MDSC generation in cancer. Interestingly,
deletion of Chop also regulated MDSC turnover, as a
delayed MDSC apoptosis and extended MDSC survival
rates were found in tumor-infiltrating MDSCs lacking
this UPR mediator, compared with CHOP-sufficient
controls [77]. Taken together, these recent findings sug-
gest that ER stress responses driven by IRE1α-XBP1
and CHOP play a major role in the regulation of mye-
loid cell activity and survival in tumors. It remains elu-
sive, however, whether the ATF6 arm of the UPR also
contributes to myeloid cell dysfunction in cancer.
Therapeutic approaches to overcome detrimental ER
stress responses in tumor-associated myeloid cells
Since the UPR appears to regulate anti-tumor immun-
ity while promoting the intrinsic aggressiveness of ma-
lignant cells, it is conceivable that therapies aimed at
attenuating ER stress or targeting UPR mediators may
have a potent double-whammy effect against cancer.
Chemical chaperones that prevent ER stress, such as
TUDCA and 4-PBA, have shown promising therapeutic
effects in preclinical cancer models. However, the con-
sequence of treatment with these compounds on the
global tumor immunoenvironment remains unknown.
Additional efforts have been made to develop specific
small-molecule inhibitors or nanoparticle-encapsulated
siRNAs targeting UPR mediators. Compounds inhibiting
the endoribonuclease domain of IRE1α, including STF-
083010, 3-ethoxy-5,6-dibromosalicylaldehyde, 4μ8C,
MKC-3946, toyocamycin, and B-I09, can block Xbp1 spli-
cing and activation in a dose dependent manner, especially
in vitro [90]. Some of these compounds have been tested
in vivo and demonstrated anti-tumor effects by directly af-
fecting the cancer cell. While the immunotherapeutic cap-
acity of these inhibitors has not been tested in vivo,
delivery of nanoparticles encapsulating Xbp1-targeting
siRNA into mice bearing metastatic ovarian carcinoma
transformed tDCs into highly immunogenic cells capable
of inducing protective T cell responses that extend host
survival [7]. Treatment of tumor-bearing mice with the
PERK small-molecule inhibitors GSK2656157 or
GSK2606414 has also resulted in significant anti-tumor
effects [49, 91], but it remains unknown whether these
compounds could additionally relieve immunosuppres-
sion in the tumor microenvironment by controlling ac-
tivation in myeloid cells, without inducing systemic
toxicity. While these studies suggest the potential of
targeting the UPR in cancer, disruptive medicinal
chemistry approaches are urgently needed to generate
more selective, potent and stable inhibitors of ER stress
sensors for in vivo use.
A major impediment to the success of current im-
munotherapies is the accumulation of suppressive
myeloid cells that prevent the generation and expan-
sion of tumoricidal T cells [92]. Therapies based on
targeting UPR mediators could be potentially used to
reprogram suppressive myeloid populations into cells that
activate anti-tumor immunity in situ. These approaches
could be useful to relieve or diminish tumor-induced
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immunosuppression prior to treatment with other im-
munotherapies such as checkpoint blockade, adoptive T
cell transfer or therapeutic vaccination. In summary,
future studies on the role of the UPR in tumor-associated
myeloid cells are expected to have a significant impact in
the development of new immunotherapies that more
effectively confront lethal cancers in the clinic.
Conclusions
Controlling the accumulation and detrimental activity of
immunosuppressive myeloid cells in cancer patients
emerges as a fundamental requirement for the success of
cancer immunotherapies. However, interventions that
effectively and permanently abolish the major regulatory
effect or the accumulation of myeloid cells in tumors are
lacking. Sustained ER stress responses have been demon-
strated to promote malignant progression and metastasis.
Further, recent studies revealed an additional role for en-
dogenous ER stress and the UPR in regulating the func-
tion, expansion and differentiation of suppressive myeloid
cells in cancer hosts. The activation of the UPR in myeloid
cells can directly occur in response to the stressful tumor
microenvironment or may be transmitted from neighbor-
ing ER-stressed cancer cells. Since disabling some ER
stress sensors and UPR mediators can reprogram suppres-
sive myeloid cells into cells that induce protective anti-
tumor immunity, new interventions capable of controlling
this pathway in vivo could improve the effectiveness of
emerging cancer immunotherapies. We therefore propose
that understanding the cellular and molecular effects of
ER stress in tumor-associated myeloid cells will be crucial
for developing more rational and hopefully definitive im-
munotherapies against lethal cancers.
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